Recent News

• 12.10.2025 - FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
• 11.26.2025 - FibroBiologics Announces Payoff of Outstanding Debt
• 11.25.2025 - FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• 11.24.2025 - FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• 11.20.2025 - FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
• 11.20.2025 - FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• 11.19.2025 - FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• 10.31.2025 - FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
• 10.24.2025 - FibroBiologics to Present at Bio-Europe 2025
• 10.14.2025 - FibroBiologics to Present at the 2025 ThinkEquity Conference

Recent Filings

• 12.03.2025 - D Notice of Exempt Offering of Securities
• 12.03.2025 - D Notice of Exempt Offering of Securities
• 11.25.2025 - 8-K Current report
• 11.25.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.25.2025 - EX-99.1 EX-99.1
• 11.20.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.19.2025 - EX-99.1 EX-99.1
• 11.19.2025 - 8-K Current report
• 10.31.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]